A detailed history of Cutler Group LP transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Cutler Group LP holds 1,100 shares of RYTM stock, worth $61,732. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,100
Previous 500 120.0%
Holding current value
$61,732
Previous $22,000 113.64%
% of portfolio
0.02%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$39.12 - $52.44 $23,472 - $31,464
600 Added 120.0%
1,100 $47,000
Q4 2023

Jan 18, 2024

BUY
$21.39 - $49.64 $10,695 - $24,820
500 New
500 $22,000
Q1 2023

May 01, 2023

BUY
$16.88 - $34.24 $1,688 - $3,424
100 New
100 $1,000
Q3 2022

Oct 25, 2022

SELL
$4.3 - $30.85 $1,444 - $10,365
-336 Reduced 25.15%
1,000 $24,000
Q2 2022

Aug 04, 2022

SELL
$3.12 - $12.25 $1,560 - $6,125
-500 Reduced 27.23%
1,336 $5,000
Q1 2022

Apr 14, 2022

BUY
$6.13 - $12.24 $11,254 - $22,472
1,836 New
1,836 $21,000
Q3 2021

Oct 26, 2021

SELL
$11.68 - $20.72 $86,642 - $153,700
-7,418 Closed
0 $0
Q2 2021

Jul 19, 2021

SELL
$18.52 - $22.55 $14,519 - $17,679
-784 Reduced 9.56%
7,418 $145,000
Q1 2021

Apr 26, 2021

BUY
$20.25 - $39.49 $70,915 - $138,293
3,502 Added 74.51%
8,202 $174,000
Q4 2020

Jan 21, 2021

SELL
$21.17 - $32.61 $14,819 - $22,827
-700 Reduced 12.96%
4,700 $139,000
Q3 2020

Oct 27, 2020

BUY
$18.13 - $30.61 $81,585 - $137,745
4,500 Added 500.0%
5,400 $117,000
Q2 2020

Jul 22, 2020

BUY
$14.41 - $25.35 $11,528 - $20,280
800 Added 800.0%
900 $20,000
Q4 2019

Feb 06, 2020

SELL
$19.53 - $25.5 $1,953 - $2,550
-100 Reduced 50.0%
100 $2,000
Q2 2019

Aug 09, 2019

BUY
$21.11 - $28.48 $4,222 - $5,696
200 New
200 $4,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.13B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.